Терапія стовбуровими клітинами при БАС (бічному аміотрофічному склерозі) в Південна Корея — підберіть 3 клініки з цінами

Stem cell therapy for ALS in South Korea is considered biologically safe. The Korean Ministry of Food and Drug Safety approved Neuronata-R in 2014. Treatments use autologous mesenchymal stem cells from the patient's own bone marrow. This minimises risks like infection or immune rejection during cerebrospinal fluid delivery.

• Regulatory status: Neuronata-R holds conditional approval from the KMFDS for ALS treatment.
• New legislation: The 2025 Regenerative Medicine Law adds national committee monitoring for patient safety.
• Safety profile: Clinical trials confirm the therapy is well-tolerated with a good safety record.
• Specialised delivery: Targeted infusion methods help reduce side effects compared to systemic treatments.

Bookimed Expert Insight: Highly specialised clinics like RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) limit intake to two patients daily. This VIP approach allows intensive monitoring. Their arterial infusion technique is unique in Korea. It aims to deliver cells closer to the affected nerve tissues than standard injections.

Patient Consensus: Seeking treatment within regulated clinical frameworks is essential. Genuine programs use the patient's own cells. This reduces the risk of rejection. Patients find comfort in Korea's established medical laws. Professional oversight provides peace of mind during the process.

Stem cell therapy in South Korea slows ALS progression. It also improves survival rates for slow-progressing patients. Specialists use Neuronata-R, an approved autologous treatment, and arterial delivery. These methods focus on neuroprotection rather than a cure. Success is highest when treatment begins within 2 years of symptom onset.

• Neuroprotection technique: Injected cells reduce inflammation and protect motor neurons from further damage.
• Clinical approval: South Korea approved the world's first commercial stem cell treatment in 2014.
• Arterial delivery: Specialist clinics like RE:YOUTH use direct arterial infusion to reach the brain.
• Survival benefit: Therapy provides long-term survival gains compared to patients using conventional therapies alone.

Bookimed Expert Insight: South Korea's clinical landscape is unique because it offers arterial delivery through clinics like RE:YOUTH. This method sends cells directly to the brain. While most hospitals use spinal injections, only 2 patients daily receive this VIP-level arterial treatment in Cheonan. This boutique approach delivers high-intensity medical attention for complex neurological cases.

Patient Consensus: Patients in South Korea report that therapy works best when viewed as a way to slow decline. The consensus highlights that while it is not a cure, it offers functional improvement. Many find the structured clinical trials more reassuring than standard commercial packages.

Neuronata-R is South Korea's officially licensed stem cell therapy for ALS. The Ministry of Food and Drug Safety granted approval for this autologous mesenchymal stem cell treatment. It uses a patient's own bone marrow cells. This slows disease progression through neuroprotective and immune-modifying effects.

• Licensed therapy: Neuronata-R is the specific product approved by Korean health regulators.
• Technique used: Specialists harvest mesenchymal stem cells from the patient's own bone marrow.
• Administration method: Doctors deliver cells via intrathecal injection into the spinal fluid.
• Main goal: The protocol aims to preserve function and reduce motor neuron inflammation.
• Clinic options: Specialised centres like RE:YOUTH also offer direct arterial stem cell infusions.

Bookimed Expert Insight: Neuronata-R is the primary regulated option. However, clinics in cities like Cheonan now perform direct arterial infusions. This approach targets systemic chronic inflammation. Bookimed data shows these facilities limit intake to two patients daily. This keeps safety standards high.

Patient Consensus: Patients travel to South Korea because the treatment follows formal research and regulatory pathways. Realistic expectations focus on slowing the decline of ALS. Patients do not expect a complete cure.

NeuroNata-R uses a patient's own bone marrow stem cells to slow ALS progression. It is a conditionally approved therapy in South Korea. The treatment releases neurotrophic factors and modulates immune responses. This protects existing motor neurons rather than replacing them in the spinal cord.

• Cell source: Autologous mesenchymal stem cells (MSCs) derived from the patient's own bone marrow.
• Delivery method: Practitioners perform intrathecal injections to deliver cultured cells directly into cerebrospinal fluid.
• Neuroprotective effect: Cells release growth factors like VEGF and BDNF to prevent motor neuron death.
• Immune modulation: The therapy shifts microglial cells to a protective state to reduce neuroinflammation.
• Outcome measurement: Treatment aims to reduce the decline of the Revised ALS Functional Rating Scale.

Bookimed Expert Insight: South Korea remains a key global hub for ALS regenerative medicine. Leading clinics like RE:YOUTH serve 1,000+ patients annually. These centres often specialise in rare disease care. They provide an approved pathway for NeuroNata-R. This pathway differs from purely experimental treatments elsewhere.

Patient Consensus: Seeking formally approved products in South Korea provides more confidence than unverified options. Most patients see this as a way to potentially slow progression. Realistic expectations are essential. It is not a cure but a regulated experimental step.

The treatment process involves a multi-stage protocol focused on neuroprotection. Specialists assess medical history remotely before harvesting Mesenchymal Stem Cells (MSCs). These cells are cultured in ministry-approved labs for several weeks. They are then delivered via intrathecal injection or direct arterial infusion. These methods bypass the blood-brain barrier.

• Remote screening: Doctors evaluate neurological exams and MRI results before patients travel.
• Cell harvesting: Specialists extract bone marrow or fat tissue for autologous cell production.
• Laboratory culturing: Ministry-approved labs expand and purify stem cells over 3–5 weeks.
• Clinical delivery: Surgeons perform intrathecal injections or arterial infusions to target nerve tissue.
• Arterial infusion: This specialised technique focuses on delivering cells directly through the arteries.

Bookimed Expert Insight: Most clinics focus on lumbar punctures. However, centres like RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) specialise in arterial infusions. They limit intake to 2 patients daily. This allows highly personalised cell delivery protocols for rare neurological conditions.

Patient Consensus: Dealing with clinics in South Korea feels organised even though most expect repeat sessions. Patients appreciate the early access to innovative therapies while staying grounded about experimental outcomes.

Patients in South Korea primarily receive autologous mesenchymal stem cells for ALS treatment through strictly regulated protocols. Clinics draw on sources like bone marrow, blood, or adipose tissue. However, the specific cell type is set by providers and trial guidelines, not patient preference.

• Licensed therapy: Neuronata-R is a conditionally approved treatment using the patient's own bone marrow cells.
• Source protocols: Specialists select autologous sources such as bone marrow or blood based on treatment goals.
• Advanced delivery: RE:YOUTH clinic in Cheonan offers specialised direct arterial infusion for targeted stem cell delivery.
• Regulatory oversight: Access to regenerative therapies is restricted to severe or rare diseases under KOIHA-accredited standards.

Bookimed Expert Insight: While South Korea ranks second globally for medical requests, specialised ALS care is highly exclusive. RE:YOUTH clinic, for example, limits intake to only 2 patients daily. This maintains VIP-level attention. This exclusivity means the complex arterial infusion protocols are managed with high precision. Every individual receives this precise care.

Patient Consensus: Patients mention that South Korean clinics follow fixed protocols. They advise getting the exact cell source and administration route in writing. Many found that these treatments slow disease progression rather than cure it.